Product Pipeline

Morphotek has leveraged its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. Through a series of collaborations with leading research institutes and commercial partners, Morphotek has gained access to validated disease targets and is developing and investigating monoclonal antibodies for the treatment of target-positive diseases.

Morphotek applies its proprietary antibody optimization technology to yield antibodies that possess high-affinity and high-titer characteristics, as well as improved effector function and cytotoxic activity, and candidates that are suitable for pharmaceutical product development.

*Ongoing confirmatory Phase 2 study in recurrent platinum-sensitive epithelial ovarian cancer patients with a low CA125 level.